172 related articles for article (PubMed ID: 11842430)
1. Farnesylated proteins and cell cycle progression.
Tamanoi F; Kato-Stankiewicz J; Jiang C; Machado I; Thapar N
J Cell Biochem Suppl; 2001; Suppl 37():64-70. PubMed ID: 11842430
[TBL] [Abstract][Full Text] [Related]
2. Failure to farnesylate Rheb protein contributes to the enrichment of G0/G1 phase cells in the Schizosaccharomyces pombe farnesyltransferase mutant.
Yang W; Tabancay AP; Urano J; Tamanoi F
Mol Microbiol; 2001 Sep; 41(6):1339-47. PubMed ID: 11580838
[TBL] [Abstract][Full Text] [Related]
3. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells.
Tamanoi F; Gau CL; Jiang C; Edamatsu H; Kato-Stankiewicz J
Cell Mol Life Sci; 2001 Oct; 58(11):1636-49. PubMed ID: 11706990
[TBL] [Abstract][Full Text] [Related]
4. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.
Basso AD; Mirza A; Liu G; Long BJ; Bishop WR; Kirschmeier P
J Biol Chem; 2005 Sep; 280(35):31101-8. PubMed ID: 16006564
[TBL] [Abstract][Full Text] [Related]
5. Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts.
Vogt A; Qian Y; McGuire TF; Hamilton AD; Sebti SM
Oncogene; 1996 Nov; 13(9):1991-9. PubMed ID: 8934546
[TBL] [Abstract][Full Text] [Related]
6. The Rheb family of GTP-binding proteins.
Aspuria PJ; Tamanoi F
Cell Signal; 2004 Oct; 16(10):1105-12. PubMed ID: 15240005
[TBL] [Abstract][Full Text] [Related]
7. Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis.
Hussein D; Taylor SS
J Cell Sci; 2002 Sep; 115(Pt 17):3403-14. PubMed ID: 12154071
[TBL] [Abstract][Full Text] [Related]
8. Targeting protein prenylation for cancer therapy.
Berndt N; Hamilton AD; Sebti SM
Nat Rev Cancer; 2011 Oct; 11(11):775-91. PubMed ID: 22020205
[TBL] [Abstract][Full Text] [Related]
9. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules.
Ashar HR; James L; Gray K; Carr D; Black S; Armstrong L; Bishop WR; Kirschmeier P
J Biol Chem; 2000 Sep; 275(39):30451-7. PubMed ID: 10852915
[TBL] [Abstract][Full Text] [Related]
10. Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways.
Gau CL; Kato-Stankiewicz J; Jiang C; Miyamoto S; Guo L; Tamanoi F
Mol Cancer Ther; 2005 Jun; 4(6):918-26. PubMed ID: 15956249
[TBL] [Abstract][Full Text] [Related]
11. Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells.
Zheng H; Liu A; Liu B; Li M; Yu H; Luo X
Cancer Lett; 2010 Nov; 297(1):117-25. PubMed ID: 20554106
[TBL] [Abstract][Full Text] [Related]
12. Farnesyltransferase inhibitors: potential role in the treatment of cancer.
Cox AD
Drugs; 2001; 61(6):723-32. PubMed ID: 11398905
[TBL] [Abstract][Full Text] [Related]
13. The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.
Ashar HR; James L; Gray K; Carr D; McGuirk M; Maxwell E; Black S; Armstrong L; Doll RJ; Taveras AG; Bishop WR; Kirschmeier P
Exp Cell Res; 2001 Jan; 262(1):17-27. PubMed ID: 11120601
[TBL] [Abstract][Full Text] [Related]
14. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents.
Ohkanda J; Blaskovich MA; Sebti SM; Hamilton AD
Prog Cell Cycle Res; 2003; 5():211-7. PubMed ID: 14593715
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines.
Mazzocca A; Giusti S; Hamilton AD; Sebti SM; Pantaleo P; Carloni V
Mol Pharmacol; 2003 Jan; 63(1):159-66. PubMed ID: 12488548
[TBL] [Abstract][Full Text] [Related]
16. Farnesylated proteins as anticancer drug targets: from laboratory to the clinic.
Russo P; Loprevite M; Cesario A; Ardizzoni A
Curr Med Chem Anticancer Agents; 2004 Mar; 4(2):123-38. PubMed ID: 15032718
[TBL] [Abstract][Full Text] [Related]
17. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
18. Increasing complexity of farnesyltransferase inhibitors activity: role in chromosome instability.
Falugi C; Trombino S; Granone P; Margaritora S; Russo P
Curr Cancer Drug Targets; 2003 Apr; 3(2):109-18. PubMed ID: 12678714
[TBL] [Abstract][Full Text] [Related]
19. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells.
Crespo NC; Ohkanda J; Yen TJ; Hamilton AD; Sebti SM
J Biol Chem; 2001 May; 276(19):16161-7. PubMed ID: 11154688
[TBL] [Abstract][Full Text] [Related]
20. Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.
de Bono JS; Tolcher AW; Rowinsky EK
Semin Oncol; 2003 Oct; 30(5 Suppl 16):79-92. PubMed ID: 14613029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
